TXMD stock icon



Market Cap: 20.8M


About: TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

Employees: 1

Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

100% more call options, than puts

Call options by funds: $32K | Put options by funds: $16K

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

6% more capital invested

Capital invested by funds: $7.32M [Q4 2023] → $7.73M (+$416K) [Q1 2024]

5% more funds holding

Funds holding: 37 [Q4 2023] → 39 (+2) [Q1 2024]

1.18% more ownership

Funds ownership: 30.74% [Q4 2023] → 31.92% (+1.18%) [Q1 2024]

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

Research analyst outlook

We haven’t received any recent analyst ratings for TXMD.

Financial journalist opinion